SLU-PP-332
$48.99
5mg
SLU-PP-332 is a synthetic small-molecule compound developed in academic research settings that functions as an agonist of estrogen-related receptors (ERRs), with preferential activity at ERRα. It has been studied for its interaction with metabolic signaling pathways, including those associated with mitochondrial function and cellular energy regulation.
In preclinical research, SLU-PP-332 has been used to explore mechanisms related to receptor-mediated transcriptional activity, mitochondrial biogenesis, and substrate utilization. It remains in investigational stages and is primarily utilized in scientific contexts to study nuclear receptor pathways and metabolic regulation.
Usage Disclaimer: Research Use Only. This product is intended strictly for laboratory research and in-vitro studies. It is not for human or animal consumption, medical use, or diagnostic purposes. Any unauthorized use of this product is strictly prohibited.
FDA Compliance: FDA Notice. The statements made regarding these products have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Research Studies
A Synthetic ERR Agonist Alleviates Metabolic Syndrome - 2024
Diet-induced obese mice | 50 mg/kg IP twice daily | 28 days | Comprehensive metabolic assessment
Landmark study demonstrating 12% body weight loss, 25% increase in fatty acid oxidation, improved glucose tolerance, and reduced hepatic steatosis. Fat mass gain was <0.5g vs ~5g in controls. No adverse pancreatic effects observed. Published in Journal of Pharmacology and Experimental Therapeutics.
Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction in Aging Kidney - 2023
21-month-old mice (equivalent to ~60-70 human years) | 8-week treatment | Comprehensive kidney function analysis
Groundbreaking aging study showing reversal of age-related kidney decline. Reduced albuminuria, prevented podocyte loss, restored mitochondrial architecture via electron microscopy, decreased inflammatory cytokines and senescence markers. First compound to directly improve mitochondrial health in aging. Published in American Journal of Pathology.
Synthetic ERRα/β/γ Agonist Induces Acute Aerobic Exercise Response - 2023
Multiple mouse models | 50 mg/kg IP | Running performance and muscle fiber analysis
First demonstration that pharmacological ERR activation replicates acute exercise genetic programs. Showed 70% increase in running time, 45% increase in distance, increased type IIa oxidative muscle fibers, and progressive grip strength improvements. ERRα confirmed as critical isoform via knockout studies. Published in ACS Chemical Biology.
Pair your peptide order with bacteriostatic water for proper reconstitution and storage. Adding it now ensures you have everything you need when your order arrives.
Avoid delays and complete your setup in one shipment.
